Bris­tol-My­ers shows off a low-pro­file AML con­tender it gained from Cel­gene buy­out — and they’re tak­ing it straight to the FDA

Bris­tol-My­ers Squibb reaped an enor­mous pipeline with its much-crit­i­cized $64 bil­lion megadeal to buy Cel­gene. And it got a few hid­den gems in the deal.

One of those gems was brought out for dis­play on Tues­day, with a late-break­er at ASH on CC-486, which is now be­ing prepped for reg­u­la­to­ry fil­ings at the FDA and else­where.

Cel­gene top-lined the pos­i­tive re­sults in a main­te­nance set­ting for acute myeloid leukemia a few months ago, but at ASH in­ves­ti­ga­tors pulled back the cur­tains on the all-im­por­tant da­ta they be­lieve will give them an ad­van­tage in the com­mer­cial wars to come.

And it’s im­pres­sive.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER